| Literature DB >> 34956173 |
Bruno C Menarim1,2, Hossam El-Sheikh Ali2,3, Shavahn C Loux2, Kirsten E Scoggin2, Theodore S Kalbfleisch2, James N MacLeod2, Linda A Dahlgren1.
Abstract
Osteoarthritis (OA) may result from impaired ability of synovial macrophages to resolve joint inflammation. Increasing macrophage counts in inflamed joints through injection with bone marrow mononuclear cells (BMNC) induces lasting resolution of synovial inflammation. To uncover mechanisms by which BMNC may affect resolution, in this study, differential transcriptional signatures of BMNC in response to normal (SF) and inflamed synovial fluid (ISF) were analyzed. We demonstrate the temporal behavior of co-expressed gene networks associated with traits from related in vivo and in vitro studies. We also identified activated and inhibited signaling pathways and upstream regulators, further determining their protein expression in the synovium of inflamed joints treated with BMNC or DPBS controls. BMNC responded to ISF with an early pro-inflammatory response characterized by a short spike in the expression of a NF-ƙB- and mitogen-related gene network. This response was associated with sustained increased expression of two gene networks comprising known drivers of resolution (IL-10, IGF-1, PPARG, isoprenoid biosynthesis). These networks were common to SF and ISF, but more highly expressed in ISF. Most highly activated pathways in ISF included the mevalonate pathway and PPAR-γ signaling, with pro-resolving functional annotations that improve mitochondrial metabolism and deactivate NF-ƙB signaling. Lower expression of mevalonate kinase and phospho-PPARγ in synovium from inflamed joints treated with BMNC, and equivalent IL-1β staining between BMNC- and DPBS-treated joints, associates with accomplished resolution in BMNC-treated joints and emphasize the intricate balance of pro- and anti-inflammatory mechanisms required for resolution. Combined, our data suggest that BMNC-mediated resolution is characterized by constitutively expressed homeostatic mechanisms, whose expression are enhanced following inflammatory stimulus. These mechanisms translate into macrophage proliferation optimizing their capacity to counteract inflammatory damage and improving their general and mitochondrial metabolism to endure oxidative stress while driving tissue repair. Such effect is largely achieved through the synthesis of several lipids that mediate recovery of homeostasis. Our study reveals candidate mechanisms by which BMNC provide lasting improvement in patients with OA and suggests further investigation on the effects of PPAR-γ signaling enhancement for the treatment of arthritic conditions.Entities:
Keywords: arthritis; joint therapy; macrophage; mevalonate pathway; oxidative stress
Mesh:
Substances:
Year: 2021 PMID: 34956173 PMCID: PMC8692379 DOI: 10.3389/fimmu.2021.734322
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1(A) Study design showing timing of bone marrow aspiration and induction of synovitis (LPS, 0.5 ng/joint) (top). Harvesting and processing of bone marrow for BMNC isolation, and normal (SF) and inflamed synovial fluid (ISF) (middle) for cell culture following depletion of native SF cells (bottom). (B) Bioinformatics pipeline used for RNA-sequencing, quantification and analysis. (C) Immunohistochemical assessment of the synovium of inflamed joints treated with BMNC leading to inflammation resolution or DPBS as a control for the expression of genes identified as upstream regulators or key in activated pathways.
Figure 2Kinetics of transcriptional signatures of BMNC cultured in SF and ISF. (A) Principal Component Analysis from 8456 genes differentially expressed (DEGs) by BMNC following culture in SF (green to blue dots; top) and ISF (yellow to red dots; bottom) for 10 days shows increasing divergence in the patterns of gene expression over time. Each dot color represents a different time point and each dot represents an individual horse. (B) Volcano plots depicting downregulated (left red quadrant) and upregulated (right red quadrant) DEGs in ISF compared to SF cultures at each time point, showing major changes at 6 days. (C) Schematic of changes in gene expression of BMNC cultured in SF (bottom) and ISF (top) for 10 days, depicting the number of DEGs over consecutive time points within groups (horizontal comparisons in SF or ISF) and between groups (vertical comparisons) at each time point (FDR ≤0.05). Numbers represent upregulated (red text) and downregulated genes (blue text) between the compared conditions.
Figure 3Differentially expressed genes (DEGs) in BMNC cultured in normal (SF) and inflamed autologous synovial fluid (ISF). (A) Heatmap of DEGs (FDR<0.05) identified among all possible comparisons (n=8456) between SF and ISF cultures over 10 days. The heatmap was created using Log10 transformed GeTMM values expressed on a color scale denoting high (red) and low (blue) expression. Each dataset (SF and ISF) included all DEGs displayed in a fixed position for comparison of the effect of culture medium over the same genes. (B) Venn diagram illustrating the intersection between DEGs identified by horizontal comparisons in either SF or ISF cultures. (C) Upset plots elucidating the intersection between DEGs identified by vertical comparisons. The nature of each intersection is indicated by the dots under the vertical bars, which denote the number of DEGs in each intersection, while horizontal bars represent the number of DEGs in each comparison.
Figure 4Weighted gene co-expression network analysis (WGCNA): module-trait relationships. (A) WGCNA of 18,038 genes in ISF identified 11 modules eigengene (ME), of which 6 were positively associated (R2≥0.7, p=≤005) with the assigned traits. The turquoise and green modules were positively associated with IL-1β quantification in ISF conditioned by BMNC. MEs blue, brown, black and pink were positively associated with the timeline. The blue module was also associated with CD86 expression assessed by flow cytometry (29). (B) In the SF dataset, analysis of the 16,318 genes identified the same 11 gene modules; however, timeline was the only trait with a positive association to MEs blue, brown, black and pink modules, as in ISF.
Figure 5Expression profile, gene ontology enrichment and overrepresented biological processes within dominant modules. The green and turquoise modules were only significant in ISF and positively associated with IL-1β quantification in conditioned ISF, and overall associated with pro-inflammatory mechanisms. The blue and brown modules were significantly associated to the timeline for both SF and ISF, while the blue module was positively associated to CD86 expression in ISF. (A) Mean expression profiles of significant modules in SF and ISF derived from all transcripts in each cluster. In ISF, the presence of the pro-inflammatory green and turquoise modules are associated to increased mean expression of the homeostatic/pro-resolving blue and brown modules. Overrepresented Biological Processes (BPs) in the blue (B), brown (C), green (D), turquoise (E) modules and their corresponding fold enrichment. The complete list of significant modules, BPs and related genes for each module is presented in , .
Top 3 most activated or inactivated pathways (Z-score > 2.0 or < -2.0; -log (p-value) > 1.3 = p>0.05) identified by IPA from DEGs between consecutive timepoints in SF and ISF.
|
| ISF | SF | ||
|---|---|---|---|---|
|
|
|
|
| |
|
| Superpathway of cholesterol biosynthesis (4.14; 10.3) | Signaling by Rho GTPases(-3.35; 8.00) | Superpathway of cholesterol biosynthesis (4.24; 8.74) | IL-5 production (-3.00; 4.43) |
| Geranylgeranyl diphosphate Biosynthesis I (via Mevalonate) (3.31; 4.88) | Leukocyte extravasation signaling (-3.20; 14.9) | Geranylgeranyl diphosphate Biosynthesis I (via Mevalonate) (3.31; 5.83) | Apoptosis signaling (-2.55; 4.13) | |
| Mevalonate Pathway I (3.00; 4.54) | IL-5 production (-3.317; 5.43) | Mevalonate Pathway I (3.00; 5.34) | Signaling by Rho GTPases (-2.35; 4.12) | |
|
| PPAR signaling (3.41; 9.22) | Acute Phase Response signaling (-4.42; 5.96) | LRX/RXR activation (3.71; 4.08) | Natural Killer cell signaling (-5.85; 4.12) |
| PPARα/RXRα activation (3.08; 9.22) | Natural Killer Cell signaling (-4.13; 6.23) | PPAR signaling (3.41; 9.89) | IL-6 signaling (-5.24; 14.9) | |
| LXR/RXR activation (2.67; 3.27) | IL-6 signaling (-4.01; 10.50) | PPARα/RXRα activation (2.59; 12.00) | Acute Phase Response signaling (-4.87; 7.31) | |
|
| Heparan Sulfate Biosynthesis (Late Stages) (2.0; 1.79) | IL-6 signaling (-2.23; 2.08) | ----------------- | ----------------- |
| Heparan Sulfate Biosynthesis (2.0; 1.66) | PRRs in Pathogen Recognition (-2.0; 1.69) | ----------------- | ----------------- | |
|
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation (2.33; 5.27) | Cell cycle control of chromosomal replication (-3.60; 8.78) | GP6 Signaling Pathway (3.05; 4.83) | EIF2 signaling (-5.456; 41.90) |
| Unfolded Protein Response (2.44; 3.23) | Kinetochore Mataphase signaling (-2.98; 16.61) | Osteoarthritis Pathway (2.53; 4.15) | Oxidative Phosphorylation (-3.00; 2.81) | |
| Netrin signaling (2.23; 1.39) | Mitotic Roles of Polo-Like Kinases (-2.12; 6.89) | Tumor Microenvironment Pathway (3.31; 2.80) | Autophagy (-2.23; 0.00) | |
In agreement with GO, dominant responses related to inflammation-derived oxidative stress and an antioxidant response relying on lipid biosynthesis and activation of the PPAR signaling pathway. While the IL-6 pathway inhibition was common to both SF and ISF, it was a more frequent in ISF cultures. A detailed list of activated and inactivated pathways is presented on .
Figure 6Heatmaps depicting the patterns of expression of genes involved in the most highly activated signaling pathways associated with resolution of synovitis, comparing BMNC cultured in SF and ISF. Further details are available at .
Figure 7Potential upstream regulators of genes differentially expressed between consecutive time points (DEGcts) in SF and ISF cultures. (A) Time window specific identification of upstream regulators analysis of the DEGcts using Ingenuity Pathway Analysis (IPA). The colored circles are upstream regulators identified for each comparison of consecutive time points with an activation or inhibition Z-score (> 2.0 or < -2.0), respectively (). Colors of the circles correspond to colors of the module eigengene from WGCNA to which that specific gene associated. Activated upstream regulators are shown at the top and those inhibited at the bottom. Upstream regulators were grouped into five categories: `Transcription regulator’, `Membrane receptor’, `Cytokine/Growth Factor (GF)’, ‘Enzyme/Kinase’ and `Other’. (B) Interaction network among activated (left) and inhibited (right) upstream regulators in BMNC cultured in ISF. Color coding of nodes relate to the corresponding module eigengene. Interaction networks reflect a response to inflammation-induced oxidative stress associated with proliferation and differentiation of BMNC into macrophages (CSF1 - green arrow), and a PPARγ-reliant inflammation resolution (red arrow), associated with inhibition of the IL-1β signaling pathway (black arrow) as suggested by complimentary analyses.
Figure 8Immunohistochemistry of synovial membranes from 6 horses with experimental synovitis treated with BMNC or DPBS. Marked resolution of inflammation was evident following BMNC therapy (31). Selected targets were potential upstream regulators of high network interaction that were differentially expressed in ISF cultures over consecutive time points, or central drivers of most activated pathways. (A) Scatterplots of composite staining scores (median, 95% confidence interval) for PPARγ (PPARG gene), phosphorylated PPARγ, PPARγ co-activator 1 alpha (PPARGC1A gene), colony stimulating factor 1 (CSF1 gene), mevalonate kinase (MVK gene), 3-Hydroxy-3-Methylglutaryl-Coenzyme A Synthase 1 (HMGCS1 gene), interleukin-1β (IL-1β gene), sirtuin 2 (SIRT2 gene), and transcription factor MAFB (MAFB gene). Each dot in the scatterplot represents the composite score for each individual horse. Tissue expression for phosphorylated PPARγ (p=0.0032) and mevalonate kinase (p=0.0291) were lower in BMNC-treated joints. (B) Representative sections of synovium from inflamed joints treated with BMNC or DPBS and stained for selected markers detailed above (scale bars 100µm).